PipelineRSS4 days ago
Cellular Intelligence acquires global rights to STEM-PD program
A company called Cellular Intelligence has bought the rights to develop a new Parkinson's disease treatment from another company called Novo Nordisk. The treatment uses stem cells (special cells that can become different types of cells) from donors. Cellular Intelligence will use artificial intelligence technology to help develop and manufacture this therapy, and Novo Nordisk is investing money in the company to support this work.
WHY IT MATTERSThis acquisition signals renewed investment in stem cell therapy for Parkinson's disease, potentially accelerating development of a treatment option that could help patients with progressive motor symptoms who have limited disease-modifying therapies available.